drugset / Trial / NCT00319670

A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children

NCT00319670

Phase 4 Completed 25 enrolled Braintree Laboratories
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate patient acceptance of a new MiraLax dose formulation in children currently treated with polyethylene glycol 3350 powder for treatment of constipation.

Timeline

Start
2006-03
Primary completion
2006-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject polyethylene glycol Other / unclassified

Indications